Necessity to evaluate PI3K/Akt signalling pathway in proarrhythmia

Area of Science:

• Cardiovascular Pharmacology
• Molecular Cardiology
• Drug Discovery

Background:

• Rising incidence of drug-induced QT prolongation and torsades de pointes necessitates understanding proarrhythmia mechanisms.
• Current antiarrhythmic strategies targeting IKr blockade have safety limitations, driving research into alternative pathways.
• The PI3K/Akt signaling pathway is implicated in cardiac ion channel function and arrhythmogenesis.

Purpose of the Study:

• To explore the role of the PI3K/Akt signaling pathway in drug-induced proarrhythmia.
• To investigate the potential of modulating this pathway for developing safer antiarrhythmic and cancer drugs.
• To highlight the need for improved drug testing methods and a deeper understanding of PI3K/Akt signaling in arrhythmogenesis.

Main Methods:

• Investigated the effects of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) on ion channel function in cardiomyocytes.
• Examined the proarrhythmic potential of PI3K inhibitors used in cancer therapy.
• Reviewed existing literature on PI3K/Akt signaling and its link to arrhythmogenesis.

Main Results:

• Cardiomyocyte dialysis with PIP3 normalized ion channel alterations and reduced proarrhythmic features.
• Reduced PI3K/Akt signaling activity is associated with proarrhythmia, while increased activity promotes cell survival.
• PI3K inhibitors used in cancer treatment have demonstrated proarrhythmic effects.

Conclusions:

• The PI3K/Akt pathway presents a potential therapeutic target for mitigating drug-induced proarrhythmia.
• Further research into PI3K/Akt signaling is crucial for developing effective antiarrhythmic drugs and evaluating cancer therapeutics.
• Enhanced drug testing strategies are needed to assess arrhythmogenic potential related to this pathway.